Goldman Sachs: Maintaining the Sage Therapeutics (SAGE.US) rating, adjusted from neutral to neutral, and adjusted the target price from $28.00 to $19.00.

Goldman Sachs: Maintaining the Sage Therapeutics (SAGE.US) rating, adjusted from neutral to neutral, and adjusted the target price from $28.00 to $19.00.

Zhitong Finance00:11

Sage Therapeutics Price Target Cut to $18.00/Share From $20.00 by Mizuho

Sage Therapeutics Price Target Cut to $18.00/Share From $20.00 by Mizuho

Dow JonesApr 26 21:24

Sage Therapeutics Is Maintained at Neutral by Mizuho

Sage Therapeutics Is Maintained at Neutral by Mizuho

Dow JonesApr 26 21:24

Canaccord Genuity Maintains Hold on Sage Therapeutics, Lowers Price Target to $17

Canaccord Genuity analyst Sumant Kulkarni maintains Sage Therapeutics with a Hold and lowers the price target from $21 to $17.

Analyst UpgradesApr 26 20:56

SAGE Therapeutics: Hold Rating Amidst Zurzuvae Success and Dalzanemdor Setbacks

TipRanksApr 26 20:35

Balancing Opportunity and Risk: Hold Rating on SAGE Therapeutics Amidst High-Stakes Catalysts and Financial Reassessment

TipRanksApr 26 20:08